Literature DB >> 11431423

Discrimination of bacterial lipoproteins by Toll-like receptor 6.

O Takeuchi1, T Kawai, P F Mühlradt, M Morr, J D Radolf, A Zychlinsky, K Takeda, S Akira.   

Abstract

Bacterial lipoproteins (BLP) trigger immune responses via Toll-like receptor 2 (TLR2) and their immunostimulatory properties are attributed to the presence of a lipoylated N-terminus. Most BLP are triacylated at the N-terminus cysteine residue, but mycoplasmal macrophage-activating lipopeptide-2 kD (MALP-2) is only diacylated. Here we show that TLR6-deficient (TLR6(-/-)) cells are unresponsive to MALP-2 but retain their normal responses to lipopeptides of other bacterial origins. Reconstitution experiments in TLR2(-/-) TLR6(-/-) embryonic fibroblasts reveal that co-expression of TLR2 and TLR6 is absolutely required for MALP-2 responsiveness. Taken together, these results show that TLR6 recognizes MALP-2 cooperatively with TLR2, and appears to discriminate between the N-terminal lipoylated structures of MALP-2 and lipopeptides derived from other bacteria.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11431423     DOI: 10.1093/intimm/13.7.933

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  349 in total

Review 1.  Toll receptors: a central element in innate immune responses.

Authors:  Thierry Vasselon; Patricia A Detmers
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

2.  Enhancing antitumor immunity perioperatively: a matter of timing, cooperation, and specificity.

Authors:  Jeffrey L Curtis; Antonello Punturieri
Journal:  Am J Respir Cell Mol Biol       Date:  2003-05       Impact factor: 6.914

3.  Differences in expression of toll-like receptors and their reactivities in dendritic cells in BALB/c and C57BL/6 mice.

Authors:  Tie Liu; Tetsuya Matsuguchi; Naotake Tsuboi; Toshiki Yajima; Yasunobu Yoshikai
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

4.  Staphylococcal superantigen-like protein 3 binds to the Toll-like receptor 2 extracellular domain and inhibits cytokine production induced by Staphylococcus aureus, cell wall component, or lipopeptides in murine macrophages.

Authors:  Ryosuke Yokoyama; Saotomo Itoh; Go Kamoshida; Takemasa Takii; Satoshi Fujii; Tsutomu Tsuji; Kikuo Onozaki
Journal:  Infect Immun       Date:  2012-06-04       Impact factor: 3.441

5.  Opposing roles of activator protein-1 and CCAAT/enhancer binding protein beta in the regulation of inducible granulysin gene expression in a human monocytic cell line, THP-1.

Authors:  Yutaka Kida; Takashi Shimizu; Koichi Kuwano
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

Review 6.  Role of TLR2-dependent inflammation in metastatic progression.

Authors:  Sunhwa Kim; Michael Karin
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

7.  Synergic effects of mycoplasmal lipopeptides and extracellular ATP on activation of macrophages.

Authors:  Takeshi Into; Mari Fujita; Tsugumi Okusawa; Akira Hasebe; Manabu Morita; Ken-Ichiro Shibata
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

8.  A novel class of lipoprotein lipase-sensitive molecules mediates Toll-like receptor 2 activation by Porphyromonas gingivalis.

Authors:  Sumita Jain; Stephen R Coats; Ana M Chang; Richard P Darveau
Journal:  Infect Immun       Date:  2013-02-04       Impact factor: 3.441

9.  Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling.

Authors:  Karen Bieback; Egil Lien; Ingo M Klagge; Elita Avota; Jürgen Schneider-Schaulies; W Paul Duprex; Herrmann Wagner; Carsten J Kirschning; Volker Ter Meulen; Sibylle Schneider-Schaulies
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy.

Authors:  Amanda Shanks Huynh; Woo Jin Chung; Hyun-Il Cho; Valerie E Moberg; Esteban Celis; David L Morse; Josef Vagner
Journal:  J Med Chem       Date:  2012-11-08       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.